![]() Blueprint Genetics Blueprint Genetics provides clinical gene testing and customized next-generation sequencing services. | ![]() 23andMe 23andMe Holding (formerly known as VG Acquisition) is a consumer genetics and research company. | ||||
Founding Date | Founding Date 2013 | Founding Date 2011 | Founding Date 2012 | Founding Date 1999 | Founding Date 2006 |
Type | Type Private | Type Public | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Burlingame, US HQ | Locations Fremont, US HQ West Wickham, GB | Locations Esbo, FI HQ Dubai, AE Seattle, US | Locations Aliso Viejo, US HQ Aliso Viejo, US | Locations Sunnyvale, US HQ South San Francisco, US |
Employees | Employees 6051% increase | Employees 22344% decrease | Employees 2191% decrease | Employees 9094% increase | Employees 56027% decrease |
Valuation ($) | Valuation ($) 1.5 b | Valuation ($) 340.9 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 169.1 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $69.6m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $189.9m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $53.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $89.9m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $15.8m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $100m (FY, 2025) |
Net income | Net income N/A | Net income ($81.3m) (FY, 2025) | Net income N/A | Net income N/A | Net income ($280.9m) (FY, 2025) |
Operating ⚠ | |||||
Patents Issued | Patents Issued N/A | Patents Issued 16 (FY, 2021) | Patents Issued N/A | Patents Issued N/A | Patents Issued 93 (FY, 2022) |
Trademark Applications (US) | Trademark Applications (US) 5 (Jul, 2022) | Trademark Applications (US) N/A | Trademark Applications (US) N/A | Trademark Applications (US) 6 (Aug, 2022) | Trademark Applications (US) N/A |
Trademarks (US) | Trademarks (US) 3 (Jul, 2022) | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) 65 (Aug, 2022) | Trademarks (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 396m | Total funding raised $ 75m | Total funding raised $ 26.3m | Total funding raised N/A | Total funding raised $ 912.5m |

Personalis is a biotechnology company that specializes in cancer genomics.
View company
Blueprint Genetics provides clinical gene testing and customized next-generation sequencing services.
View company
Ambry Genetics is a company that provides genetic testing solutions.
View company
23andMe Holding (formerly known as VG Acquisition) is a consumer genetics and research company.
View company